Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Colorcon
Merck
Johnson and Johnson
Medtronic

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR TIMOLOL MALEATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Timolol Maleate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004641 ↗ Prevention of Esophageal Varices by Beta-Adrenergic Blockers Completed Yale University Phase 3 1993-08-01 The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00004641 ↗ Prevention of Esophageal Varices by Beta-Adrenergic Blockers Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 1993-08-01 The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00006398 ↗ Prevention of Esophageal Varices by Beta-Adrenergic Blockers Completed Yale University Phase 3 1993-08-01 The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00006398 ↗ Prevention of Esophageal Varices by Beta-Adrenergic Blockers Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 1993-08-01 The purpose of this study is to learn whether timolol is useful in preventing or delaying the appearance of gastroesophageal varices, a complication that may develop in the future as a consequence of liver disease. Cirrhosis causes an increased resistance of blood flowing through the liver. This leads to an increased pressure in the portal vein (the vein that takes blood to your liver). High portal pressure is responsible for the appearance of complications of chronic liver disease such as varices and variceal bleeding (bleeding from veins in your esophagus). Timolol belongs to a group of medications called beta-blockers. Beta-blockers decrease high portal pressure and previous studies have shown that beta-blocker pills are useful in preventing bleeding from varices in patients who already have varices. A more desirable effect would be if these pills could prevent not only bleeding from varices but the appearance of varices (and therefore of bleeding).
NCT00108017 ↗ Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2005-04-01 This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
NCT00273442 ↗ Assessing Cosopt Switch Patients Completed Pharmaceutical Research Network Phase 4 2005-11-01 To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.
NCT00273481 ↗ Cosopt Versus Xalacom Completed Pharmaceutical Research Network Phase 4 2005-09-01 To compare the intraocular pressure efficacy and safety of the DTFC given twice daily versus the LTFC given once every morning following a run-in period with timolol maleate given twice daily.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Timolol Maleate

Condition Name

Condition Name for Timolol Maleate
Intervention Trials
Ocular Hypertension 35
Glaucoma 18
Open-angle Glaucoma 14
Primary Open Angle Glaucoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Timolol Maleate
Intervention Trials
Glaucoma 47
Ocular Hypertension 40
Hypertension 34
Glaucoma, Open-Angle 34
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Timolol Maleate

Trials by Country

Trials by Country for Timolol Maleate
Location Trials
United States 114
Spain 8
Canada 4
Germany 4
United Kingdom 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Timolol Maleate
Location Trials
California 10
Massachusetts 8
New York 7
Georgia 7
New Jersey 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Timolol Maleate

Clinical Trial Phase

Clinical Trial Phase for Timolol Maleate
Clinical Trial Phase Trials
Phase 4 20
Phase 3 17
Phase 2 14
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Timolol Maleate
Clinical Trial Phase Trials
Completed 47
Recruiting 6
Active, not recruiting 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Timolol Maleate

Sponsor Name

Sponsor Name for Timolol Maleate
Sponsor Trials
Alcon Research 8
Aerie Pharmaceuticals 5
Allergan 5
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Timolol Maleate
Sponsor Trials
Industry 47
Other 27
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Medtronic
McKinsey
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.